Abbott Laboratories has announced plans to release its fourth-quarter 2025 financial results before markets open on Thursday, January 22, 2026, giving investors an early look at the healthcare giant’s performance as it closes out the year.
The company confirmed that following the earnings release, management will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) to discuss the results in detail. Investors and analysts can access the call through Abbott’s Investor Relations website, providing an opportunity to hear directly from leadership about the company’s financial health and strategic outlook.
Can’t make the live call? An archived version will be made available later that same day, the company stated in its announcement, allowing stakeholders flexible access to the information.
Global Healthcare Presence
Abbott’s quarterly results are closely watched by market analysts as a bellwether for the broader healthcare sector. With 114,000 employees serving more than 160 countries, the company’s reach extends across multiple healthcare segments including diagnostics, medical devices, nutritionals, and branded generic medicines.
“Abbott is a global healthcare leader that helps people live more fully at all stages of life,” the company noted in its release, highlighting its diverse portfolio of “life-changing technologies” that span the healthcare spectrum.
The upcoming earnings report will likely provide insights into how Abbott’s various business segments have performed in a constantly evolving healthcare landscape. Investors will be particularly interested in growth areas and how the company is navigating ongoing market challenges.
This quarterly financial checkpoint represents more than just numbers on a balance sheet — it’s a window into how one of healthcare’s most established players is adapting to industry shifts and positioning itself for future growth. The results could have ripple effects across pharmaceutical, medical device, and diagnostic markets worldwide.
